November 30, 2015
Pfanstiehl Establishes Asian Subsidiary
Pfanstiehl, a leading US-based manufacturer of cGMP high purity, low endotoxin injectable grade excipients and biopharmaceutical components for upstream bioprocessing, downstream formulation, and specialty applications, has announced the establishment of its Asian subsidiary, Pfanstiehl Singapore Pte. Ltd. The subsidiary will be anchored in Singapore, but will provide the foundation to support Pfanstiehl’s growing customer base throughout the Asia-Pacific region.
April 2, 2015
Pfanstiehl Establishes European Subsidiary
Pfanstiehl, a leading US-based manufacturer of cGMP high purity, low endotoxin injectable grade excipients and biopharmaceutical components for upstream bioprocessing, downstream formulation, and specialty applications, has announced the establishment of its European subsidiary, Pfanstiehl GmbH. The subsidiary will be anchored in Switzerland, but will provide the foundation to support Pfanstiehl’s growing customer base throughout Europe, the Middle East, and Africa.
January 20, 2015
Pfanstiehl Launches cGMP-produced, Parenteral Grade Ribose for Pharmaceutical Applications
Pfanstiehl has announced the launch of its high purity, low endotoxin, Ribose (USP/NF, EP, JP), manufactured in the US under strict cGMP, ICH Q7 compliant conditions. “Ribose is a unique monosaccharide that is being investigated for its potential in a wide variety of therapeutic indications, including heart conditions, chronic fatigue syndrome, and athletic performance/recovery. We are pleased to be able to make such a high quality, emerging technology available for our clients,” says Dr. Christopher Wilcox, VP, Sales & Marketing at Pfanstiehl. Ribose has shown potential to reduce symptoms of fibromyalgia and improve quality of life in patients dealing with congestive heart failure. Despite the early nature of many of these studies, having a fit for purpose, high purity grade of ribose should encourage researchers to develop the full potential of this molecule.
January 20, 2015
Pfanstiehl Launches New cGMP-produced, Parenteral Grade Maltose for Pharmaceutical Formulations
Pfanstiehl has announced the launch of a new high purity, low endotoxin, Maltose (USP/NF, EP, JP), manufactured in the US under strict cGMP, ICH Q7 compliant conditions. “Maltose is a multifunctional disaccharide used to stabilize protein therapeutics, intravenous IG infusions and as a bioprocessing aid. We are pleased to be able to make such a high quality material available for our clients,” says Dr. Christopher Wilcox, VP, Sales & Marketing at Pfanstiehl. Maltose has demonstrated a unique ability to prevent aggregation in IVIG solutions and to act as a bulking agent in final formulations. It should be considered alongside other tried and true carbohydrates such as trehalose, sucrose, and sorbitol when developing platforms for stabilizing mAbs, ADCs, and vaccines.
December 1, 2014
Pfanstiehl Launches cGMP-produced, Parenteral Grade Mannitol for Pharmaceutical Formulations
Pfanstiehl has announced the launch of a new high purity, low endotoxin, Mannitol (USP/NF, EP, JP), manufactured in the US under strict cGMP, ICH Q7 compliant conditions. “Mannitol is a tried and true platform excipient used in a wide range of therapeutic formulations. We are pleased to be able to make such a high quality material available for our clients,” says Dr. Christopher Wilcox, VP, Business Development at Pfanstiehl. Mannitol has demonstrated its utility as a stand-alone lyoprotectant or bulking agent, as well as in combination with other high purity excipients like trehalose and sucrose to stabilize a variety of systems including mAbs, ADCs, vaccines, and small molecules.
September 30, 2014
Pfanstiehl Launches cGMP-produced Mannose for Cell Culture Media Optimization & Glycoprotein Biosynthesis
Pfanstiehl has announced the launch of cGMP-produced, high purity Mannose (USP/NF, EP), manufactured in the USA under ICH Q7 compliant conditions. “Mannose has long been recognized for playing a key role in protein glycosylation. Now, there is a growing body of evidence that media supplementation with mannose can improve overall culture performance and consistency of protein glycosylation,” according to Dr. Christopher Wilcox, VP, Business Development at Pfanstiehl. “Process scientists have made great strides in elevating monoclonal antibody expression levels in mammalian cell lines, but have observed that product quality can often suffer or be a source of inconsistency. Having a ready source of high purity mannose available for media enhancement will add a valuable tool to the media toolkit for innovators and biosimilar producers while serving to expand awareness of this carbohydrate’s positive attributes”. Read more…
September 4, 2014
Pfanstiehl Gearing Up for Potent API Expansion
Pfanstiehl is now making public what many industry experts have suspected was the case ever since the entrepreneurial contract development and manufacturing organization (CDMO) shed its parent firm (Ferro) just over a year ago. The firm is aggressively investing in its potent API contract manufacturing capabilities at its US-based cGMP facility located north of Chicago. This expansion has taken the form of new state of the art equipment, updated permanent and flexible containment solutions, open development and manufacturing capacity, top tier technical & business development personnel, as well as a new collaborative culture focused on delivering customized solutions to clients from early development / toxicology through drug commercialization. Read more…
March 24, 2014
Reinvigorated Pfanstiehl Launches Its New cGMP-Produced, Non-Animal Derived Galactose, Targeting Upstream Bioprocessing Applications.
Since shedding Ferro in April of 2013, the newly independent Pfanstiehl has been carefully considering its options to bring a new generation of formulation and bioprocessing solutions to its biopharma clients worldwide. Known for nearly a century for its first in class carbohydrate chemistry expertise, Pfanstiehl has built a reputation on high quality, cGMP-produced excipients and highly potent APIs at its Waukegan, Illinois headquarters. Cynthia Kerker, Pfanstiehl’s President, states, “We have a renewed focus on delivering solutions to the challenges brought to us by our customers. We believe that by smartly expanding our High Purity excipients portfolio, we will enable our clients to achieve their formulation goals without sacrificing quality.” Read more…
April 1, 2013
Med Opportunity Partners, LLC makes strategic investment in Pfanstiehl, Inc.
Med Opportunity Partners, LLC (“MEDOP”), a Greenwich CT-based private equity firm focused
exclusively on the health care sector, announced today its acquisition of Ferro Pfanstiehl Laboratories, Inc., a global leader in cGMP carbohydrates and Active Pharmaceutical Ingredients (APIs), from Ferro Corporation. MEDOP, a strategic, operating-oriented investment firm, brings significant resources, pharmaceutical and biopharmaceutical relationships, and capital to fuel the Company’s growth. Read more…/